2024 版 EGFR 20 外显子插入突变非小细胞肺癌中国专家共识要点解读

金炫宏; 周斐

doi:10.3971/j.issn.1000-8578.2025.25.0120

2024 版 EGFR 20 外显子插入突变非小细胞肺癌中国专家共识要点解读

金炫宏^{1, 2},
周斐^3,

1.
浙江大学
2.
浙江大学医学院附属邵逸夫医院肿瘤科
3.
同济大学附属东方医院肿瘤科

基金项目: (23ZR1453500)上海市自然科学基金项目编号: ;(81703020)国家自然科学基金项目编号:

计量
- 文章访问数: 506
- HTML全文浏览量: 58
- PDF下载量: 228
出版历程
- 收稿日期: 2025-02-23
- 录用日期: 2025-04-07
- 网络出版日期: 2025-04-13

Interpretation of Key Points in the 2024 Chinese Expert Consensus on EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer

Xuan-hong JIN^{1, 2},
Fei ZHOU^3,

摘要

摘要: 随着对表皮生长因子受体（EGFR）20外显子插入突变（ex20ins）非小细胞肺癌（NSCLC）的深入研究，以及多项新型靶向药物临床数据的相继公布，中国临床肿瘤学会（CSCO）NSCLC专家委员会在参考最新国内外文献和临床数据的基础上，组织肺癌领域专家结合实际经验，对2023版中国专家共识进行了全面更新。《EGFR 20外显子插入突变非小细胞肺癌规范化诊疗中国专家共识（2024版）》围绕该罕见突变的精准检测与规范化治疗策略进行了优化调整。本文重点解析了2024版共识中新增的推荐与修订内容，并梳理了未来研究和临床实践的探索方向，以期为临床诊疗提供更科学、更精准的指导依据。
- _：非小细胞肺癌 /
- EGFR 20外显子插入突变 /
- 靶向治疗策略
Abstract: With the growing understanding of epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC) and the emergence of new clinical data from targeted therapies, the Chinese Society of Clinical Oncology (CSCO)
　　NSCLC Expert Committee has updated the 2023 Chinese expert consensus. Based on the latest domestic and international literature, clinical evidence, and expert experience, the "Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)" introduces refinements in the diagnostic and therapeutic strategies for this rare mutation. This article highlights the key updates and recommendations in the 2024 consensus compared to the 2023 version and outlines future directions to optimize clinical practice and improve patient outcomes.
- Non-small cell lung cancer /
- EGFR exon 20 insertion /
- Targeted therapy strategies